Labyrinthopeptins as virolytic inhibitors of respiratory syncytial virus cell entry.
Antiviral activity
Human respiratory syncytial virus (hRSV)
Labyrinthopeptin
Lanthipeptide
Virolytic
Virus entry
Journal
Antiviral research
ISSN: 1872-9096
Titre abrégé: Antiviral Res
Pays: Netherlands
ID NLM: 8109699
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
25
10
2019
revised:
03
02
2020
accepted:
12
03
2020
pubmed:
22
3
2020
medline:
2
4
2021
entrez:
22
3
2020
Statut:
ppublish
Résumé
Acute lower respiratory tract infections (ALRI) caused by respiratory syncytial virus (RSV) are associated with a severe disease burden among infants and elderly patients. Treatment options are limited. While numerous drug candidates with different viral targets are under development, the utility of RSV entry inhibitors is challenged by a low resistance barrier and by single mutations causing cross-resistance against a wide spectrum of fusion inhibitor chemotypes. We developed a cell-based screening assay for discovery of compounds inhibiting infection with primary RSV isolates. Using this system, we identified labyrinthopeptin A1 and A2 (Laby A1/A2), lantibiotics isolated from Actinomadura namibiensis, as effective RSV cell entry inhibitors with IC
Identifiants
pubmed: 32197980
pii: S0166-3542(19)30614-X
doi: 10.1016/j.antiviral.2020.104774
pii:
doi:
Substances chimiques
Antiviral Agents
0
Bacteriocins
0
labyrinthopeptin A1, Actinomadura namibiensis
0
labyrinthopeptin A2
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
104774Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The antiviral activity of Laby A1/A2 against a broad spectrum of enveloped viruses has been patented (PCT/EP2016/078143). Otherwise, no competing financial interests exist.